Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women

Post time 2022-7-2 13:27:28

journal：Applied Health Economics and Health Policy

Authors：Nidhi Gupta; Dharna Gupta; Jyoti Dixit; Nikita Mehra; Ashish Singh; Manjunath Nookala Krishnamurthy; Gaurav Jyani; Kavitha Rajsekhar; Jayachandran Perumal Kalaiyarasi; Partha Sarathi Roy; Prabhat Singh Malik; Anisha Mathew; Pankaj Malhotra; Sudeep Gupta; Lalit Kumar; Amal Kataki; Shankar Prinja

Published date：2022-7-

DOI：10.1007/s40258-022-00731-2

Article link：http://dx.doi.org/10.1007/s40258-022-00731-2

Article Source：Springer Science and Business Media LLC。

Remark：

Post time 2022-7-2 13:27:29

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2022-7-2 13:37:49

: This post has been completed
Completed attachments will be deleted within 24 hours.

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women